All analysed cfDNA-based biomarkers exhibited gradually increased levels of methylation for the control, BPH, and PCa groups, except methylated CCDC181, indicating slightly (but not significantly) increased methylation levels in BPH patients compared to the control and PCa groups. This evidence concerns the gene CCDC181 and benign prostatic hyperplasia.